1. A randomized, controlled trial evaluating the efficacy and safety of BTH1677 in combination with bevacizumab, carboplatin, and paclitaxel in first-line treatment of advanced non-small cell lung cancer. Issue 1 (27th February 2018) Authors: Engel-Riedel, Walburga; Lowe, Jamie; Mattson, Paulette; Richard Trout, J.; Huhn, Richard D.; Gargano, Michele; Patchen, Myra L.; Walsh, Richard; Trinh, My My; Dupuis, Mariève; Schneller, Folker Journal: Journal for immunotherapy of cancer Issue: Volume 6:Issue 1(2018) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. P859 Association of immunopharmacodynamic responses of imprime PGG plus pembrolizumab with clinical benefit in metastatic triple negative breast cancer (TNBC) subjects failing front-line chemotherapy. (15th April 2020) Authors: Ottoson, Nadine; Bose, Nandita; Chan, Anissa; Qiu, Xiaohong; Harrison, Ben; Walsh, Richard; Mattson, Paulette; Gargano, Michele; Cox, Joanna; Chisamore, Michael; Uhlik, Mark; Graff, Jeremy Journal: Journal for immunotherapy of cancer Issue: Volume 8(2020)Supplement 1 Page Start: A8 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. P862 Clinical benefit potentially evident with immunopharmacodynamic responses in prior-checkpoint failed metastatic melanoma patients treated with imprime PGG and pembrolizumab. (15th April 2020) Authors: Chan, Anissa; Bose, Nandita; Bose, Nandita; Ottoson, Nadine; Qiu, Xiaohong; Harrison, Ben; Walsh, Richard; Mattson, Paulette; Gargano, Michele; Cox, Joanna; Chisamore, Michael; Uhlik, Mark; Graff, Jeremy Journal: Journal for immunotherapy of cancer Issue: Volume 8(2020)Supplement 1 Page Start: A10 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗